b2-AR activation increases the risk of sudden cardiac death (SCD) in heart failure (HF) patients. Non-selective b-AR blockers have greater benefits on survival than selective b1-AR blockers in chronic HF patients, indicating that b2-AR activation contributes to SCD in HF. This study investigated the role of b2-AR activation on repolarization and ventricular arrhythmia (VA) in the experimental HF model. The guinea pig HF was induced by descending aortic banding. The effective refractoriness period (ERP), corrected QT (QTc) and the incidence of VA were examined using Langendorff and programmed electrical stimulation. Ikr and APD were recorded by the whole cell patch clamp. Selective b2-AR agonist salbutamol significantly increased the incidence of VA, prolonged QTc and shortened ERP. These effects could be prevented by the selective b2-AR antagonist, ICI118551. Salbutamol prolonged APD90 and reduced Ikr in guinea pig HF myocytes. The antagonists of cAMP (Rp-cAMP) and PKA (KT5720) attenuated Ikr inhibition and APD prolongation induced by salbutamol. However, the antagonists of Gi protein (PTX) and PDE III (amrinone) showed opposite effects. This study indicates that b2-AR activation increases the incidence of VA in the experimental HF model via activation of Gs/cAMP/PKA and/or inhibition of Gi/PDE pathways.
T he prevalence of heart failure (HF) is approximately 2.6% in Western societies and annual incidences approach 5-10 per 1000 persons, making it a major health problem 1 . Approximately 50% of HF patients die suddenly predominantly due to lethal ventricular arrhythmias 2 . However, the underlying mechanism for the occurrence of lethal ventricular arrhythmias in HF is still unclear.
The sympathetic nervous system plays a vital role in the pathophysiology of HF. High cardiac sympathetic activities have been reported to be correlated with the risk of death from arrhythmias 3 . b adrenergic receptors (bARs), a superfamily of G-protein-coupled receptors, contribute to the cardiac sympathetic activity. b1-ARs are primarily expressed in the heart and comprise 75-80% of cardiac b-ARs. However, non-selective b-AR blockers have shown greater benefits in survival than selective b1-AR blockers in patients with chronic HF 4 , indicating that b2-AR or b3-AR activation might contribute to SCD in HF instead of b1-AR. Contrary to b3-AR, which is primarily expressed in adipose tissue and minimally in the heart, b2-AR is expressed in the heart and accounts for 20-25% of cardiac b-ARs. In addition, b2-AR genetic variants increase the risk of sudden cardiac death (SCD) in human 5 . Abnormal augmentation of cardiac responsiveness to b2-AR is also a risk factor for ventricular fibrillation 6 . These facts indicate that b2-AR activation might be responsible for SCD in HF. The rapid component of delayed rectifier potassium current (Ikr), mediated by the human ether-a-go-gorelated gene (hERG) 7 , is a major contributor to phase 3 repolarization of the action potential 8 . Its reduction often increases action potential duration (APD) and leads to the increase of the incidence of early afterdepolarizations (EADs), which can induce ventricular arrhythmias and sudden cardiac death 9, 10 . Our previous study revealed that Ikr was significantly lower in HF myocytes and increased response to b2-AR stimulation augments inhibition of IKr in HF myocytes 11 . Thus, b2-AR activation may delay repolarization and induce ventricular arrhythmia in HF by Ikr suppression and APD prolongation.
b2-AR, a G protein-coupled receptor, regulates cardiac function upon binding to catecholamine and leads to the activation of heterotrimeric G-proteins 12 . b2-AR couples dually to Gs proteins and pertussis toxin (PTX)-sensitive Gi proteins 13 , leading to the activation of AC and production of cAMP 14 . Phosphodiesterases (PDE) regulates cAMP production through AC activation and cAMP breakdown to modulate PKA activity and myocardial contractility 15 . However the possible roles of b2-AR activation in repolarization and ventricular arrhythmia in HF have not yet been determined.
Here we hypothesized that b2-AR activation could induce abnormal repolarization and ventricular arrhythmia through Gs/cAMP/ PKA and Gi/PDE. To address this hypothesis, we used b2-AR agonist and antagonist to determine cardiac electrophysiological changes in guinea pigs HF model and investigated the effects of b2-AR activation on Ikr and APD in HF left ventricular myocytes using the whole cell patch clamp technique. From this study, we preliminary clarified the mechanisms of b2-AR activation governing cardiac repolarization and arrhythmogenesis in heart failure.
Results b2-AR stimulation increases the incidence of ventricular arrhythmia from isolated failing heart. In the control hearts, VA was induced in only one in six hearts perfused with salbutamol, and no VA was evoked by an extrastimulus application in the other two groups. Incidence of PES-induced VA dramatically increased in the HF groups (Fig. 1 ). PES significantly increased the incidence of VA in the HF hearts compared to the control preparations after perfusion of salbutamol (83.3% vs. 16.7%, n 5 6, p , 0.05) (Fig. 1B) . ICI118551 significantly decreased inducibility of PES-evoked VA in the HF hearts exposed to salbutamol (16.7% vs. 83.3%, n 5 6, p , 0.05) (Fig. 1B) .
b2-AR activation prolongs QTc from isolated failing heart. In the control hearts, the selective b2-AR agonist salbutamol slightly prolonged QTc compared to the control group (262.2 6 7.29 ms vs 240.8 6 6.07 ms, n 5 6, p , 0.05) (Fig. 2B) . However, salbutamol significantly broadened QTc of HF hearts compared to HF hearts perfused without salbutamol (293.5 6 6.60 ms vs. 258.7 6 6.65 ms, n 5 6, p , 0.01) (Fig. 2B) . The percentage increase in QTc was significantly larger in the HF hearts than in the control hearts (13.52 6 1.72% vs. 8.87 6 0.84%, n 5 6, p , 0.05) (Fig. 2C) . To determine if b2-AR mediated QTc broadening was induced by salbutamol, the hearts were perfused with selective b2-AR antagonist ICI118551 for 30 min prior to salbutamol. ICI118551 significantly limited QTc prolongation induced by salbutamol in the control (239.7 6 7.29 ms vs. 262.2 6 7.29 ms, n 5 6, p , 0.05) (Fig. 2B ) and HF groups (264.5 6 9.29 ms vs 293.5 6 6.60 ms, n 5 6, p , 0.05) (Fig. 2B ).
b2-AR stimulation shortens effective refractory period of LV in HF model. In this study, the effective refractory period was examined by extrasystolic stimulation and dynamic pacing from the isolated heart twelve weeks after procedure. HF dramatically prolonged LV ERP compared to the control group (82.50 6 4.79 ms vs. 68.33 6 3.07 ms, n 5 6, p , 0.05) (Fig. 3B ). In the control hearts, no significant difference was observed in ERP in the presence or absence of salbutamol (62.33 6 3.36 ms vs. 68.33 6 3.07 ms, n 5 6, p . 0.05). However, salbutamol significantly shortened ERP in HF group (67.25 6 3.35 ms vs. 82.50 6 4.79 ms, n 5 6, p , 0.05) and salbutamol-induced ERP shortening was inhibited by ICI118551 (82.00 6 4.55 ms vs. 67.25 6 3.35 ms, n 5 6, p , 0.05) (Fig. 3C ).
b2-AR stimulation prolongs APD90 in myocytes from isolated failing heart. APD at 90% repolarization (APD90) was prolonged to a greater extent by salbutamol in the HF group compared to the control group (14.11 6 1.10 ms vs. 7.04 6 1.59 ms, n 5 6 p , 0.01) (Fig. 4B) . However, no significant difference was observed in change of 50% repolarization (APD50) between the HF and control groups (9.44 6 1.85 ms vs. 4.61 6 2.65 ms, n 5 6, p . 0.05) (Fig. 4B ).
b2-AR activation inhibits Ikr in myocytes from isolated failing heart. Twelve weeks after aortic constriction, left ventricular myocytes isolated from the hearts of the control and HF groups were used to measure Ikr and APD stimulated by salbutamol by the whole-cell patch-clamp technique (Fig. 5 ). The mean current densities of Ikr in the control and HF groups were shown in Fig. 5B . The Ikr tail current density in the HF group was significantly decreased by salbutamol compared to control group (36.5 6 3.35% vs. 22.84 6 3.97%, n 5 6, p , 0.05).
Gs proteins promote the prolongation effect of b2-AR stimulation on APD in ventricular myocytes. Salbutamol slightly increased APD90 and APD50 in the control cells, but no significant difference was observed in these cells in the presence or absence of Rp-cAMP (4.08 6 1.67% vs. 7.53 6 1.66%, n 5 6, p . 0.05; 3.09 6 3.00% vs. 4.70 6 2.67%, n 5 6, p . 0.05) (Fig. 6A ). In the HF cells, Rp-cAMP significantly reduced the percentages of prolongation of APD90 and APD50 by salbutamol compared to salbutamol only (3.99 6 0.80% vs. 14.22 6 1.18%, n 5 6, p , 0.01; 3.64 6 1.07% vs. 11.84 6 2.13%, n 5 6, p , 0.05) (Fig. 6A) .
The effect of PKA on salbutamol-induced prolongation of APD was similar to cAMP. KT5720 did not significantly decrease the degree of broadened APD90 and APD50 by salbutamol in the control cells (3.69 6 2.63% vs. 7.53 6 1.66%, n 5 6, p . 0.05; 2.98 6 5.08% vs. 4.70 6 2.67%, n 5 6, p . 0.05) (Fig. 6A) . However, this effect was dramatically prevented by KT5720 in the HF cells. The difference in percentage prolongation of APD90 was significant between salbutamol with and without KT5720 (4.74 6 2.00% vs. 14.22 6 1.18%, n 5 6, p , 0.01) (Fig. 6A) , and the change of APD50 was the same as that in APD90 (3.75 6 1.88% vs. 11.84 6 2.13%, n 5 6, p , 0.05) (Fig. 6A ).
Gi proteins weaken the prolongation effect of b2-AR stimulation on APD in ventricular myocytes. To investigate the effect of Gi protein on b2-AR activation-induced APD prolongation, we studied the effects of PTX on changes in APD in the control and HF myocytes after perfusion with salbutamol. No difference was observed in APD90 and APD50 with or without PTX in the control cells (9.61 6 0.94% vs 7.53 6 1.66%, n 5 6, p . 0.05; 8.77 6 1.44% vs 4.70 6 2.67%, n 5 6, p . 0.05, Fig. 6B ). After treatment with PTX in the HF cells, the percentages of prolongation of APD90 and APD50 induced by salbutamol were greater than those without PTX administration (18.74 6 1.11% vs. 14.22 6 1.18%, n 5 6, p , 0.05; 18.3 6 1.85% vs. 11.84 6 2.13%, n 5 6, p , 0.05) (Fig. 6B) .
We further determined the effects of PDE on salbutamol-induced APD prolongation. The results of amrinone were similar to that of PTX. Amrinone had no significant effects on salbutamol-induced APD90 and APD50 broadening in the control cells (10.32 6 0.51% vs. 7.53 6 1.66%, n 5 6, p . 0.05; 9.78 6 0.78% vs. 4.70 6 2.67%, n 5 6, p . 0.05) (Fig. 6B) . However, APD prolongation was dramatically augmented by amrinone in the HF cells, and the percentage prolongation of APD90 and APD50 was greater with salbutamol and amrinone compared to salbutamol with no amrinone (19.95 6 1.34% vs. 14.22 6 1.18%, n 5 6, p , 0.01, 18.79 6 1.53% vs 11.84 6 2.13%, n 5 6, p , 0.05) (Fig. 6B) .
Gs proteins promote the inhibitory effect of b2-AR stimulation on Ikr in ventricular myocytes. Rp-cAMP reduced the inhibitory effect of salbutamol on Ikr in the control group from 22.78 6 4.16% to 10.41 6 2.97% (n 5 6, p , 0.05) (Fig. 7A ) and dramatically attenuated the inhibitory effect of salbutamol on Ikr in the HF group (from 36.97 6 3.56% to 11.44 6 1.75%, n 5 6, p , 0.01) (Fig. 7A) .
To investigate whether PKA correlated with decreased Ikr response to b2-AR, we explored the effects of KT5720 on the reduction of salbutamol stimulated Ikr. Salbutamol-induced inhibition of Ikr was attenuated by KT5720 in the control group (from 22.78 6 4.16% to 12.73 6 1.32%, n 5 6, p , 0.05) (Fig. 7A ) and the HF group (from 36.97 6 3.56% to 17.70 6 1.88%, n 5 6, p , 0.01) (Fig. 7A) .
Gi proteins weaken the inhibitory effect of b2-AR stimulation on Ikr in ventricular myocytes. No significant difference was observed in the reduction of Ikr between cells from the control group with or without PTX (27.88 6 2.13% vs. 22.78 6 4.16%, n 5 6, p . 0.05) (Fig. 7B) . However, the reduction of Ikr was significantly greater in the HF group with the presence of PTX compared to that with the absence of PTX (46.63 6 2.40% vs. 36.97 6 3.56%, n 5 6, p , 0.05) (Fig. 7B) .
This study showed that the effects of PDE on b2-AR activation were similar to those on Gi. In the control cells, amrinone did not further decrease Ikr compared to cells treated with salbutamol only (26.39 6 1.79% vs. 22.78 6 4.16%, n 5 6, p . 0.05) (Fig. 7B) . The effects of b2-AR activation on Ikr were augmented by amrinone in HF cells in contrast to those not pretreated with amrinone (49.25 6 1.05% vs. 36.97 6 3.56%, n 5 6, p , 0.05) (Fig. 7B) .
Discussion
The major findings of this study are as follows: (1) b2-AR activation prolongs QTc and APD90, shortens ERP and increases the incidence of VA in isolated failing heart. (2) Inhibition of Gs/cAMP/PKA pathway reduces the incidence of VA and the suppression of Gi/ www.nature.com/scientificreports PDE pathway increases the incidence of VA induced by b2-AR activation in chronic HF. To the best of our knowledge, this study for the first time showed that Gs and Gi pathway are involved in the occurrence of VA induced by b2-AR activation.
First, b2-AR activation prolongs repolarization, shortens effective refractory period and increases the incidence of VA in isolated failing heart. b-adrenergic receptors are composed of three subtypes, b1, b2 and b3-adrenergic receptors, and stimulation by the sympathetic nervous system or circulating catecholamine is involved in cardiac myocytes 13 . Previous studies have shown that b1 proteins are significantly reduced and b2 proteins remain unchanged in HF hearts; thus, the proportion of b2 protein increase might indicate the prominence of b2 proteins in the diseased condition 11, 13 . As early as the 1980s, the b2-adrenoceptor agonist salbutamol was found to have beneficial hemodynamic effects to patients with HF, but also had increased incidence of ventricular tachycardia 16 . Catecholamine increased repolarization dispersion and induced VA by b2-adrenoceptor activation 17 . b2-AR antagonist ICI118551 significantly reduced incidence of ventricular fibrillation 18 . QT interval reflects the total duration of ventricular depolarization and repolarization or integrated APD of heart cells. Accumulating evidence has demonstrated that the major ionic current responsible for QT prolongation is the rapid delayed rectifier K1 current (Ikr) 19 . Our results showed that APD was significantly broadened in HF ventricular myocytes following Ikr inhibition stimulated by b2-adrenoceptor agonist. Meanwhile, the ERP in LV and QTc was dramatically prolonged by salbutamol in isolated failing hearts. Thus, b2-adrenoceptor activation might participate in VA in HF, which had been suggested as a more refined assessment for the risk of SCD in HF.
Second, the inhibition of Gs/cAMP/PKA and Gi/PDE pathway shows opposite effects on the incidence of VA induced by b2-AR activation in chronic HF. Cardiac b2-AR couples dually to Gs and Gi proteins 20, 21 . Ikr is a target for cAMP/PKA regulation. A-kinase anchoring proteins (AKAPs) target PKA to hERG channels, contributing to the acute regulation of Ikr by cAMP 22 . Phosphorylation of hERG resulted from activation of cAMP-dependent PKA brings about a rapid reduction in current amplitude 23 . Our results further demonstrated that cAMP/PKA was involved in the inhibitory effect of b2-AR activation on Ikr. The b2AR-Gs signaling had positive effects on AC activity, cAMP synthesis, and PKA activation, but negative responses mediated by Gi 13 . It has been reported that myocyte apoptosis was induced when the coupling of b2AR to Gi was inhibited 24 . In addition, PDE attenuated contractility and cAMP production mediated by b2-AR in rat ventricular myocardium; Gi protein also limited isotropic effects of salbutamol mediated by b2-AR 25 . In our studies, Gi and PDE inhibitors enhanced Ikr reduction and APD prolongation induced by b2-AR agonist in HF myocytes. These results demonstrated that Gi protein contributed to b2-AR agonist induced Ikr inhibition and APD prolongation, oppositely to Gs protein. However, the precise mechanism for b2-AR activationinduced inhibition of IKr for HF myocytes remains unclear.
Third, phosphodiesterase inhibitors affected the incidence of VA in chronic heart failure. Mirinone and amrinone inhibit phosphodiesterase and suppress degradation of cAMP 26 . PDE3 inhibitors improve cardiac contractility by cAMP pathways. However, chronic treatment with PDE3 inhibitors deteriorates HF and lead to sudden death 27 . Milrinone has been used as an independent risk factor for clinically significant tachyarrhythmia in the early postoperative period after congenital heart surgery 28 . Moreover, PDE5 inhibitors have already been reported to have a concentration-dependent inhibitory effect on Ikr and prolongation of cardiac repolarization 29 . Interestingly, most PDE inhibitors decreases hERG current directly or indirectly while two PDE3 inhibitors (amrinone and milrinone) fail to exhibit any hERG inhibitory effects 30 . In this study, amrinone did not inhibit Ikr current in the control and HF myocytes, consistent with previous reports 30 . However, our studies further showed that Ikr currents were inhibited by salbutamol after pretreatment with PDE3 inhibitor, and APD was prolonged more. Thus, PDE3 inhibitor combined with b2-AR activation might prolong cardiac repolarization by blocking Ikr and improving the incidence of VA in HF patients. Lowdose b-blockers in combination with milrinone has also been reported to improve cardiac function in acute decompensated HF patients with tachycardia 31 , with the addition of low-dose b-blockers preventing hemodynamic deterioration due to tachycardia.
In summary, our study elucidated the potential mechanism of b2-AR activation in the inhibition of Ikr and prolongation of APD. b2-AR stimulation induced VA in failing hearts through activating the Gs/cAMP/PKA pathway. Gi/PDE was involved in cardiac repolarization prolongation induced by b2-AR activation, but the effects were opposite to Gs/cAMP/PKA; Inhibition of Gs/cAMP/PKA pathway could reduce the incidence of ventricular arrhythmias induced by b2-AR activation in chronic HF. In addition, suppression of Gi/ PDE pathway can increase incidence of VA. These findings showed that Gs/cAMP/PKA and Gi/PDE could be important therapeutic targets for preventing the occurrence of VA in HF.
Methods
All experiments were performed in accordance with the protocols approved by the Institutional Animal Care and Use Committee and the Guide for the Care and Use of Laboratory Animals of Nanjing Medical University, China.
Establishment of guinea pig heart failure model. Male guinea pigs (250-280 g) were divided into two groups: Control and HF. The animals in HF groups were injected with atropine sulfate (0.1 mg/kg) to inhibit mucus secretion. Thirty minutes later, they were anaesthetized with intraperitoneal pentobarbital (30 mg/kg) and then intercostal space and the descending aorta was exposed. A metal tube (1 to 2 mm in external diameter and 1 cm in length) was tied to the vessel using a 2-0 surgical ligature and the tube was removed followed by closing the chest incision. Sham animals underwent the same operation, with the exception that the aortae were not banded. Sham-operated animals were used as controls.
Langendorff preparation and ex vivo ECG recordings. The HF and control guinea pigs were anaesthetized with pentobarbital (30 mg/kg) and anti-coagulated with sodium heparin (100 U). After the chest was open, the heart was removed and immediately suspended in a Langendorff apparatus. Heart preparations were perfused via the aorta at a constant pressure of 50 mmHg-60 mmHg with warm To investigate the different effects of b2-AR activation on QTc, isolated hearts from the HF and control groups were exposed to salbutamol (10 mm) (Selleckchem, Houston, TX, USA). After 10-min stabilization, ECGs were taken until the hearts were perfused with salbutamol for 10 min.
Programmed ventricular stimulation. Heart preparations were stimulated with 2-ms rectangular pulses and twice the diastolic threshold current through a bipolar electrode at the LV apex. Continuous pacing was started with a cycle length of 200 ms (S1-S1 interval), and a premature extrastimulus (S2) was delivered after each 8 beats, while the interval (S1-S2) was progressively shortened by 10 ms until loss capture had occurred. The longest S1-S2 interval which failed to capture the ventricle was the effective refractoriness period (ERP). The programmed electrical stimulation protocol was invoked until ventricular arrhythmia was induced or until the protocol was exhausted.
To investigate the incidence of ventricular arrhythmia (VA), we used the programmed electrical stimulation (PES) to stimulate left ventricle of the isolated heart. The control and HF hearts were both divided into three sub-groups including the control, salbutamol and salbutamol plus ICI118551 groups.
Isolation of cardiac myocytes. The myocytes were isolated from guinea pig hearts by enzymatic technique as described previously 11 with minor modification. After the heart was removed, the ascending aorta was mounted onto a Langendorff perfusion system. The preparation was first perfused at 37uC with Tyrode's solution. The heart was then perfused with Ca 21 -free Tyrode's solution for 5 min, followed by perfusion with the same buffer with the addition of 0.4 mg/mL collagenase type II and 1% bovine serum albumin. Until the heart was soft, the left ventricular myocytes were gently separated and kept in KB solution (in mM): KOH 85, KCl 30, KH 2 PO 4 Cell Electrophysiological recordings. Cells were transferred to a recording chamber continuously perfused with the bath solution. Pipettes had resistances of 3-6 MV. Whole-cell patch-clamp currents were measured with an Axopatch 200B (Axon, USA). The flow rate was maintained at 2-3 mL/min.
For Ikr recording, pipette solution and bath solution were prepared as our previously described 11 . Briefly, the slow component of the delayed rectifier potassium currents (I ks ) were blocked by 10 mM chromanol (Sigma, St. Louis, MO, USA) and calcium currents were ablated by 10 mM nifedipine (Sigma, St. Louis, MO, USA) in the bath solution. Salbutamol was dissolved in distilled water at a final concentration of 10 mM; chromanol was dissolved in dimethyl sulfoxide (DMSO) to reach a concentration of 10 mM and KT5720 was at the concentration of 1 mM, the solutions were stocked at 220uC until use. Final concentration of DMSO was less than 0.5% in bath, which has been shown without effects on currents 11 . To record the I kr , the following test pulse protocol was used: from a holding potential 240 mV, test pulses were applied at various voltages from 240 mV to 140 mV (step width 10 mV, and step duration 200 ms each) prior to returning to 240 mV for tail current recording 32 . APs were evoked using whole-cell current-clamp mode by suprathreshold current pulse of 5 ms duration at the frequency of 1 Hz. APD was measured at 90% repolarization (APD90) and 50% repolarization (APD50). APs were generated with the same amplifier and recorded at 37 6 5uC.
To investigate whether the inhibitory effects of b2-AR activation on APD and Ikr were mediated by cAMP, an inhibitory cAMP analog Rp-cAMP (100 mM) (Sigma, St. Louis, MO, USA) was added to the pipette solution; To investigate whether PKA correlated with change of Ikr and APD response to b2-AR, the ventricular myocytes from the control and HF groups were incubated with KT5720 (2.5 mM) (Sigma, St. Louis, MO, USA) for 1 h. To determine whether the Gi signaling pathway also mediated b2-AR-induced inhibition of Ikr or prolongation of APD, cells were pretreated with Gi protein inhibitor PTX (400 ng/mL) (Tocris, San Francisco, CA, USA) and PDE inhibitor amrinone (30 mM) (Sigma, St. Louis, MO, USA) respectively. After 1-h incubation, Ikr and APD before and after the application of salbutamol in ventricular myocytes were recorded.
Statistical analysis. Measurement data were expressed as mean 6 S.E.M. As to the analysis of the data, normality in the repeated measures was tested with Shapiro Wilk Test and statistical analysis was performed with student's T test and one-way ANOVA. The P-value reported was two-sided and value of less than 0.05 was considered statistically significant. All analyses were performed using the SPSS software (Version 13.0, SPSS Inc., Chicago, IL, USA).
